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Background: High levels of participation in cervical screening are reported in Canada from the 1970’s as a result of
early uptake of the Pap smear and universal Medicare. Despite recommendations to the contrary, the programs
have featured early age of initiation of screening and frequent screening intervals. Other countries have achieved
successful outcomes without such features. We analyzed national data to better understand mortality and incidence
trends, and their relationships to screening.
Methods: The Canadian Cancer Registry, National Cancer Incidence Reporting System, and the Canadian Vital
Statistics Database were used to measure mortality and incidence rates. Cases and deaths from invasive cervical
cancer were classified by 5 year age groups at diagnosis and death (15 to 19 years through to 80 to 84 years), year
of diagnosis (1972 to 2006), and year of death (1932 to 2006). Probabilities of developing and dying from cervical
cancer were calculated for age-specific mortality and incidence. The proportion of women reporting a timely Pap
test was estimated for 1978 to 2006.
Results: Cervical cancer mortality has declined steadily from a peak of 13.5 to 2.2 per 100,000 (83%,) between 1952
and 2006, and 71% between 1972 and 2006. Incidence of invasive cervical cancer has declined by 58% since 1972.
These declines have occurred more among older age groups than younger. Invasive cervical cancer incidence and
mortality is less in each successive birth cohort of women. Participation rates in screening are high especially in
women under age 50.
Conclusions: Despite increasing risk factors for cervical cancer, both incidence and mortality have declined over
time, across age groups, and across birth cohorts. Earlier increasing mortality (1932 – 1950) was likely related to
improved classification of cancers and the early subsequent reduction (1950 – 1970) to improved treatment. Recent
improvements in incidence and mortality are likely due to high rates of screening. For women under age 30 years
there are low rates of disease but lesser improvement related to screening.
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Cervical cancer is one of the most common cancers
among women worldwide: third in incidence overall [1].
In Canada, cervical cancer was frequent, but now ranks
11th for incidence and 16th for cancer-related mortality
[1-3]. Approximately 1,300 women were diagnosed and* Correspondence: dickinsj@ucalgary.ca
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reproduction in any medium, provided the orabout 350 women died from the disease in Canada dur-
ing 2011 [4,5].
Canada was an early adopter of cervical cancer screen-
ing from 1949 in British Columbia with gradual intensi-
fication across the country [6]. Beginning in the 1960’s,
intensification of screening was linked to oral contracep-
tive prescriptions and pre- and post-natal care resulting
in high screening rates among women younger than
35 [6,7]. In the early 1970’s cervical cancer screening
became partially subsidized and ultimately free of charge
in 1984. Thereafter, uptake of screening increased [8]. By
1973, the screening rate was near 50%, and by 1997, over
75% among women between 18 and 64 years [7]. Duringral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ginning at age 18 or even younger and ceasing at age
69 [9,10]. By 1976, screening was linked to a reduction
in mortality from cancer of the uterus as a whole, which
includes cancer of the cervix [11]. Screening was
adopted without a randomized trial to demonstrate its
efficacy, and there is limited data to elucidate which ages
or subgroups of women should be screened [12]. The
need for screening at ages younger than 25 has been ques-
tioned because of the low incidence and high rates of
false positives, causing large numbers of referrals for
colposcopy [13].
The understanding that nearly all cervical cancer is
caused by oncogenic strains of the human papilloma-
virus (HPV) has assisted in better interpretation of the
associations between behavior and cervical cancer. The
United Kingdom has observed fluctuations of cervical
cancer incidence: women who reached early adulthood
in times of war had higher rates than those who matured
during peace [14,15]. Other European countries have
demonstrated changes in incidence and mortality because
of period and cohort effects related to the coverage and
effectiveness of screening policies [16,17].
Canada has near universal availability of cervical
screening, and has had policies encouraging starting
screening early in life and repeating frequently. There is
also high quality long-term national data on mortality
and incidence. To assess the effect of this intense
screening, we used national data on mortality and inci-
dence to analyze changes in the mortality and incidence
of invasive cervical cancer over time, by age group andTable 1 Reduction in age specific mortality rates from invasive





15 to 19 0 0 * *
20 to 24 9 0.3 5 0.1
25 to 29 51 1.7 30 0.6
30 to 34 137 4.7 66 1.8
35 to 39 223 8.3 121 3.8
40 to 44 337 14.3 167 5.3
45 to 49 417 21.0 280 8.9
50 to 54 357 21.0 303 10.1
55 to 59 325 21.9 326 12.9
60 to 64 357 28.2 319 14.3
65 to 69 311 28.5 281 15.6
70 to 74 238 27.7 244 17.6
75 to 79 176 32.9 234 23.2
80 to 84 81 28.3 135 20.9
*Deaths, mortality rate and mortality reduction is not provided due to small numbebirth cohort, and relate this to screening activity and
other factors that have affected this cancer.Methods
Data sources
Mortality data were obtained from the Canadian Vital
Statistics Database (1950 – 2006) and annual Statistics
Canada publications (1932–1949) [18,19]. Incidence
data were obtained from the Canadian Cancer Registry
(1992 – 2006) and the National Cancer Incidence
Reporting System (1972 – 1991) [4,19,20]. Multiple
primary coding rules of the International Agency for
Research on Cancer were utilized [21]. For incidence,
cancers (C53) were classified according to the Inter-
national Classification of Disease for Oncology Third
Edition. For mortality, cancers (C53) were classified
according to the International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision
[22,23]. Deaths were included when cervical cancer was
determined to be the underlying cause of death. Popula-
tion estimates were obtained from Statistics Canada
[18,24-42] and are based on intercensal estimates from
1932 – 2005 and post censal estimates for 2006 and
2007. Estimates from 1932 to 1970 were not adjusted for
enumeration undercounts resulting in small relative
drops in incidence for the years from 1971. For 1971 the
ratio of the adjusted estimate to the unadjusted census
population estimate for women is 1.015. Direct age
standardization was performed using the Canadian 1991
population as standard.cervical cancer in Canada: 1952 – 2006 and 1972 – 2006







0 0.0 –* –*
9 0.2 –* –*
31 0.6 –* –*
65 1.2 75 32
105 1.7 79 54
172 2.5 82 52
197 3.1 85 66
223 3.9 81 61
186 3.8 82 70
145 3.9 86 73
141 4.6 84 70
149 5.4 81 70
145 6.0 82 74
155 8.3 71 60
rs of cases and the resulting susceptibility to spurious variation.
Figure 1 Age standardized mortality and incidence of cervical cancer in Canada.
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lected de-identified data were analysed within the confi-
dential environment of the Public Health Agency of
Canada by their staff (JO, AS, LP), and only aggregate
data were released, following standard rules for suppres-
sion of cells containing very small numbers.
Analysis
Data were classified by 5 year age groups at diagnosis
and death (15 to 19 years through to 80 to 84 years),Table 2 Reduction in age specific incidence rates from invasiv
1972 – 2006
Age Group 1972 – 1976
New Cases Rate (per 100,000)
1972 to 1976
15 to 19 15 0.3
20 to 24 143 2.7
25 to 29 429 9.1
30 to 34 643 17.1
35 to 39 660 20.7
40 to 44 787 25.0
45 to 49 924 29.4
50 to 54 919 30.6
55 to 59 822 32.5
60 to 64 752 33.8
65 to 69 629 34.9
70 to 74 456 32.9
75 to 79 314 31.1
80 to 84 182 28.2year of diagnosis (1972 to 2006) and year of death
(1932 to 2006). The 80 to 84 age group was chosen as
the cut-off because it was the eldest available 5-year
age group. Incidence and mortality rates for each
category were calculated by dividing the number of cases
or deaths in each category by the census population.
Percent reductions among 5-year age groups were calcu-
lated using five-year period mortality and incidence rates.
Denominators were not adjusted for hysterectomy. Rates
based on 1 to 5 observations for incidence and 1 toe cervical cancer in Canada: 1952 – 2006 and
2002 – 2006 % Incidence
















Figure 2 Age-specific mortality from invasive cervical cancer in Canada, 1972–2006.
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dentiality purposes
Probabilities of developing and dying from cervical
cancer were calculated for age-specific mortality (1952,
1972 and 2006) and incidence (1972 and 2006). Respective
life tables were based on 1951 to 1953, 1971 to 1973 and
2005 to 2007 all-cause mortality rates. Calculation of the
probability of developing and dying from cancer were
based on standard methods [43,44].
Data used to estimate the proportion of women with a
timely Pap test uptake were obtained from the Canada
Health Survey 1978–1979, Health Promotion Survey
1985, 1990, National Population Health Survey 1994–
1995, 1996–1997, 1998–1999, and Canadian Community
Health Survey cycles 1.1 (2001), 2.1 (2003), 3.1 (2005),
and Canadian Community Health Survey - Annual
Component, 2008. Timely cervical cancer screening was
defined as having had a pap smear test within 3 years for
all surveys except the CHS 1978–79 which used a two
year period. Denominators for these survey reports were
adjusted for hysterectomy from 1996–1997 onwards.
Detailed information on the above survey designs, sample
sizes and methodologies is available upon request.Results
Overall
Age standardized mortality from invasive cervical cancer
declined 83% from 1952 to 2006 (13.2 to 2.2 per 100,000
women respectively). About half of the decline occurred
between 1972 and 2006 (7.7 to 2.2 per 100,000 women
respectively) (Table 1 & Figure 1). Age-standardized in-
cidence declined 58% between 1972 (22.3 per 100,000)
and 2006 (9.4 per 100,000) (Figure 1 & Table 2). This
was notable over the age of 40, with lesser effects below
that age, except for a relative reduction of 50% for
women aged 20–24. Figures 2 and 3 show a steady
sequential reduction of age-specific mortality and inci-
dence from 1972 to 2006. The greatest declines in both
mortality and incidence are observed in age groups over
45 years with reductions as high as 74% in mortality and
69% in incidence (Tables 1 & 2).Trends by calendar year
After initial rises in mortality for older women, there
was a steady decline among women younger than
60 years from the 1940s, and among women over
Figure 3 Age-specific incidence of invasive cervical cancer for 5 year periods, 1972–2006.
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dence declined for all age groups from 1972 to 2006,
most apparent in women above age 30 and the reduction
was larger at ages over 45 years (Figure 5).Trends by birth cohort
Age-specific mortality and incidence were compared by
birth cohorts for women born between 1890 and 1989
(Figures 6 & 7). A steady progression to lower mortality
from the earliest to the most recent birth cohorts is
observed with peak mortality dropping from 28.2 deaths
to 4.1 deaths per 100,000 women. Peak mortality rates
occurred at progressively younger ages from the 1890–
94 cohort to 1930–34 cohort. The most recent birth
cohorts (1940 to 1989), have lower initial increases in
mortality but rates continue to rise with age and it is not
possible to discern whether they will drop after the 4th
decade. Women among the earliest birth cohorts experi-
enced twice the peak incidence of invasive cervical can-
cer than women in the birth cohorts after 1950
(Figure 7). In 1952, the lifetime probability of death from
cervical cancer (percent) was 0.94, by 1972 it was 0.66,
and by 2006, 0.22. The lifetime probability of developing
invasive cervical cancer fell from 1.54 to 0.66 (1972 and
2006 respectively).Uptake of screening
Canada-wide community health surveys show consistent
rates of cervical screening between 1978 and 2006: over
40% among 18–19 year-olds, rising to mostly over 80%
during the young adult ages, then dropping thereafter,
especially after age 70 (Table 3). The rates are lower in
the 1978–9 survey, largely accounted for by the two-year
definition of timely uptake.
Discussion
Incidence and mortality from invasive cervical cancer
has declined in Canada since the 1950s. For most age
groups mortality has declined by over 80% since the
1950s and 50% since the 1970s respectively (Table 1)
while incidence declined by more than 50% since the
1970s (Table 2). Mortality reductions are small for
women under the age of 30 and greater for older
women, with the largest reductions over the age of
50 years. Period analysis suggests rising mortality for
older age groups until the 1950s and 1960s, then steady
reductions for all age groups from the 1970s. Birth
cohort analysis demonstrates differing trajectories be-
tween the most recent and distant cohorts: among recent
cohorts small increases in mortality rates with age peak
at approximately 4 deaths per 100,000 women, compared
to over 24 deaths per 100,000 women among those born
Figure 4 Mortality from invasive cervical cancer in Canada, 1932–2006: trends by year of death.
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steady reductions for all age groups, especially over age
40, and extrapolating backwards suggests that Canada
previously had a substantially higher incidence.
Reductions in both mortality and incidence are influ-
enced by changes in the quality of death certification
and disease registration, improvement in diagnosis and
treatment, and screening for early disease. The increases
in mortality before 1950 are likely due to classification
errors (see data limitations). Subsequent reductions were
initially probably related to introduction of effective
treatment. In the post-World War II era of 1950 to
1970, the specialty of gynecology developed rapidly, ini-
tial treatment of cancer was done by well-trained
gynecological surgeons, and radiotherapy became readily
available across the country. Gynecological oncology as
a specialty became widely available in the 1970s and 80s.
These developments led to improved diagnosis and
treatment, and likely contributed to the trends seen
in mortality before 1975. Analysis of data from the
Karolinska hospital in Sweden, together with trends in
mortality from cancer of the cervix in that country,
suggested that the introduction of radiotherapy for
cancer of the cervix led to an important reduction in
cervix cancer mortality [45]. Treatment techniques haveonly changed incrementally since then with addition of
more effective chemotherapy [46], so are likely to have
made smaller differences to mortality from about 1980,
but mortality from cervical cancer in Canada continues
to decline substantially. There was an apparent spike in
incidence between about 1972 and 1980, most evident
for women in the youngest age groups. This is clear in
the data from British Columbia, a province that has a
longer data series (Figure 8). Pathologists active at the
time ascribed this to artefact due to the introduction of
colposcopy, leading to more frequent use of punch biop-
sies that were difficult to assess, and produced more
“over-diagnosis” of lesions that would regress. (personal
communication D van Niekerk). This likely occurred
across the country and exaggerated the apparent reduc-
tions in incidence based on national data from 1972–
1976, especially at younger ages, where this artefact is
greater in proportion to the total.
Screening rates in Canada have been consistently high
from early ages and persisting until age 70, especially
notable after 1996–7 when hysterectomy corrections
were applied to the analyses (Table 3 [47] These high
proportions are not adjusted for sexual activity but
screening has been associated with the practice of pre-
scribing contraception and pre and post-natal care,
Figure 5 Incidence of invasive cervical cancer in Canada, 1972–2006: trends by year of diagnosis.
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screened. This has occurred despite most screening
being opportunistic: programs of systematic population-
based reminders and recall have only commenced in
recent years in some provinces [47]. Recent immigrants,
those with lower incomes and rural women are less
likely to have regular screening [48,49], so there is scope
for improvement, as has been shown for aboriginal
women [50].
A further factor that could affect both incidence and
mortality of cervical cancer is change in the underlying
epidemiology of infection and carcinogenesis by HPV.
This could be influenced by behavior change or by im-
migration from countries with high cervical cancer rates.
Relevant behaviour change may include early com-
mencement of sexual activity, increased number of part-
ners (not only of women, but of their consorts),
smoking, and oral contraceptive use [12]. These might
be expected to increase incidence rates, especially from
the late 1960s when oral contraceptive use becamewidespread, and women in the cohorts born between
1930 and 1950 steadily increased smoking behaviour.
Further, Canada has experienced substantial immigration
since the 1950s, initially from Europe, then from various
Asian countries, South America and Africa. Many of
these areas have high cervical cancer rates [1], but immi-
grant women are less likely to be screened [48,49], so
immigration may have attenuated the decrease in inci-
dence and mortality that is observed.
Cervical screening is effective largely because it
increases detection of pre-cancer (CIN, Ca-in-situ), and
treatment prevents progression to invasive cancer [16].
Therefore the observed reductions in incidence are most
likely due to screening, especially since risk factors have
increased. If cancer still develops in a screened popula-
tion, it is usually detected at an earlier stage and is
therefore more amenable to curative treatment, so the
program reduces mortality by two mechanisms. Some
effect of screening began from 1949, in parallel with
improved treatments, and in the 1960s when screening
Figure 6 Mortality from invasive cervical cancer in Canada, 1932–2006: trends by year of birth.
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clearly related to screening [11]. Since then it has
dropped yet more, despite minimal advances in treat-
ment and the increased risk factors noted, so the con-
tinuing reduction can be ascribed to screening. From the
1990s, the rate of decrease has flattened out: which
may be partly due to greater difficulty in reaching some
segments of the population, and partly from reaching
the limit of what can be achieved with screening. Adeno-
carcinoma of the cervix is less amenable to cytological
screening, and while this used to comprise a small
fraction, as squamous carcinomas are removed, they
become a larger fraction [51,52]. In addition, more rap-
idly growing cancers are difficult to detect by screening
and to treat [16].
Countries that have not instituted widespread screen-
ing have observed little change in cervical cancer mor-
tality or incidence [53]. Substantial drops in incidence
and mortality from cervical cancer in Canada have fol-
lowed a different pattern from those found in the United
Kingdom (UK) and some other European countries over
the same period [17]. Canada showed a substantialreduction of incidence about a decade before the UK,
where gynecological oncology treatment was also well
developed but a major program of organized cervical
screening was not introduced until 1988 [16]. The
United Kingdom has observed fluctuations of cervical
cancer incidence that relate to behaviours: women who
reached early adulthood in times of war had higher rates
than those before and after [14,15]. By contrast, Canada
experienced no increase that can be ascribed to infection
during the war years, nor after the introduction of oral
contraception in the late 1960s.
The effect of screening is age dependent: mortality
changes in the age groups under 25 are too small to as-
sess in this analysis, and for those aged 25–29, most of
the reduction occurred before 1972, so may have been
as much due to treatment as screening. The greatest
reductions both in proportion and numbers occur in
mature women, about half before 1972–6. Thus it is
likely that treatment reduced mortality, but screening
added to this effect. Since it became widespread, screen-
ing has probably reduced the need for treatment of
advanced disease, but at the cost of treating minor
Figure 7 Incidence of invasive cervical cancer in Canada, 1972–2006: trends by year of birth.
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sors, causing artefactual increases in incidence especially
among young women at the time that colposcopy was
introduced. This artefact makes it difficult to accurately
quantify the effect of screening on incidence among the
lowest age groups. A limited effect of screening on redu-
cing incidence under the age of 30 was found in a UK
case control study [54].
The reduction in mortality from cervical cancer has
been very similar in Canada, the United States and Fin-
land [16]. Finland has an organized program, with
screening every 5 years, largely restricted to women age
30–59. Programs of annual screening in North America
over a much wider age range than Finland have placed a
greater burden on women, causing more harm in terms
of follow-up and over-treatment of early disease, and
used far more medical resources, especially among
women under age 30 years [13]. An IARC working
group has recommended that screening should not start
in any country before the age of 25 [12]. As the era of
HPV testing arrives, policies must be planned to obtain
a better balance of benefit, effort and harm, across
all ages.Limitations of the data
This analysis was limited by four issues: misclassification
prior to 1950, adjustment for hysterectomy, small num-
bers of cases among young women, and data availability.
Firstly, although there have been no substantial changes
in classification of cervical cancer in the ICD codes,
prior to the 1970s there was misclassification of
advanced disease between cervical and uterine cancer
[6]. Consequently, early mortality data is likely to under-
estimate cervical cancer deaths. Much of the apparent
rise in mortality prior to 1950 is probably due to
improved classification. Secondly, incidence and mortal-
ity rates were not adjusted for hysterectomy and are
therefore underestimated. This is particularly relevant
for estimates among women over 45 years of age, when
most hysterectomies occur. In Canada the hysterectomy
rate peaked in approximately 1972, and prevalence was
as high as 30% for women over 55 years [55]. However,
there is insufficient hysterectomy data for us to accur-
ately estimate hysterectomy-corrected rates by age over
the whole period. An analysis on data to 1976 suggested
that changing hysterectomy rates did not affect the fall
in cervical cancer due to screening [56]. Since then,





















18-19 43.2 (35.6 - 51.2) 49.3 (41.6 - 57.0) 54.2 (43.4 - 65.1) 48.5 (40.2 - 56.8) 49.6 (43.0 - 56.1) 44.0 (33.5 - 54.5) 43.8 (40.8 - 46.7) 47.3 (44.0 - 50.6) 42.4 (39.1 - 45.6) 39.8 (35.0 - 44.7)
20-24 77.3 (74.1 - 80.2) 83.4 (80.8 - 86.1) 75.4 (70.1 - 80.6) 71.1 (65.2 - 77.0) 72.8 (68.6 - 77.0) 72.5 (67.3 - 77.7) 65.9 (63.7 - 68.1) 70.4 (67.7 - 73.1) 70.0 (67.6 - 72.3) 73.9 (70.7- 77.3)
25-29 86.8 (84.9 - 88.4) 90.9 (88.0 - 93.8) 85.5 (82.6 - 88.4) 83.8 (80.1 - 87.5) 85.5 (82.5 - 88.4) 86.8 (82.8 - 90.8) 80.4 (78.5 - 82.2) 81.3 (79.3 - 83.2) 82.5 (80.7 - 84.2) 81.3 (78.6 - 84.1)
30-34 79.7 (75.0 - 83.7) 90.9 (88.0 - 93.8) 84.5 (79.5 - 89.6) 83.7 (80.5 - 86.9) 87.3 (85.2 - 89.4) 87.1 (83.9 - 90.4) 81.7 (80.0 - 83.4) 84.6 (83.0 - 86.2) 85.0 (83.6 - 86.4) 83.1 (80.6 - 85.6)
35-39 74.3 (70.1 - 78.1) 83.6 (80.6 - 86.6) 82.5 (76.7 - 88.3) 80.9 (76.8 - 85.0) 84.5 (82.1 - 86.8) 85.7 (82.5 - 88.9) 80.5 (78.8 - 82.2) 82.2 (80.5 - 84.0) 82.0 (80.3 - 83.6) 83.2 (80.6 - 85.7)
40-44 67.8 (63.0 - 72.2) 83.5 (80.5 - 86.5) 81.3 (75.6 - 87.0) 79.2 (74.6 - 83.0) 81.5 (78.4 - 84.6) 82.9 (78.7 - 87.2) 80.3 (78.8 - 81.7) 82.8 (81.0 - 84.6) 81.2 (79.5 - 82.8) 81.9 (78.8 - 84.9)
45-49 70.1 (64.6 - 75.1) 79.2 (72.9 - 85.5) 77.8 (71.3 - 84.4) 75.4 (70.8 - 79.9) 79.6 (76.2 - 83.1) 83.9 (79.3 - 88.6) 78.6 (76.7 - 80.5) 81.3 (79.5 - 83.0) 78.6 (76.6 - 80.7) 82.3 (79.4 - 85.1)
50-54 63.8 (56.5 - 70.4) 74.9 (69.2 - 80.6) 75.2 (68.4 - 82.0) 73.5 (68.0 - 79.1) 80.9 (78.0 - 83.7) 85.2 (81.2 - 89.2) 79.8 (77.7 - 81.9) 80.8 (79.1 - 82.5) 79.7 (77.8 - 81.6) 77.4 (73.8 - 81.0)
55-59 57.3 (51.3 - 63.1) 69.0 (62.7 - 75.4) 69.3 (62.8 - 75.8) 62.3 (55.5 - 69.1) 72.5 (68.1 - 77.0) 80.5 (74.9 - 86.1) 77.4 (74.9 - 79.8) 81.9 (80.3 - 83.5) 77.6 (75.8 - 79.4) 76.9 (73.3 - 80.5)
60-64 42.1 (36.1 - 48.3) 69.7 (64.1 - 75.2) 65.1 (58.5 - 71.8) 60.9 (54.1 - 67.7) 64.8 (59.8 - 69.8) 74.1 (67.5 - 80.7) 72.8 (69.6 - 76.1) 74.7 (72.6 - 76.8) 75.0 (73.1 - 76.9) 71.5 (67.9 - 75.1)
65-69 41.3 (35.6 - 47.1) 59.8 (52.1 - 67.4) 55.1 (47.3 - 62.9) 56.4 (50.4 - 62.4) 55.9 (50.4 - 61.4) 61.8 (54.5 - 69.1) 64.8 (61.8 - 67.8) 65.0 (62.6 - 67.4) 63.0 (60.5 - 65.4) 66.8 (62.9 - 70.8)
70-74 28.3 (21.8 - 35.8) 50.8 (42.9 - 58.8) 41.1 (32.0 - 50.1) 35.7 (29.9 - 41.5) 46.1 (41.3 - 50.8) 55.4 (46.8 - 64.0) 50.8 (47.6 - 54.0) 54.0 (51.4 - 56.6) 51.6 (49.3 - 53.9) 48.7 (43.8 - 53.5)
75-79 19.6 (14.1 - 26.6) 43.5 (33.0 - 54.0) 33.0 (23.6 - 42.5) 31.3 (25.2 - 37.4) 33.7 (28.0 - 39.5) 40.2 (31.1 - 49.3) 37.7 (34.4 - 41.1) 38.1 (35.1 - 41.1) 35.7 (32.9 - 38.4) 27.6 (22.7 - 32.4)
80-84 15.2 (9.4 - 23.5) 43.4 (30.9 - 55.9) 35.0 (21.8 - 48.2) 27.6 (18.4 - 36.8) 26.1 (21.0 - 31.2) 26.9 (16.4 - 37.3) 23.9 (20.8 - 27.1) 23.7 (21.0 - 26.5) 23.3 (20.5 - 26.0) 21.4 (17.2 - 25.7)
Timely uptake is defined as within the last 2 years (1978/79) or within the last 3 years (1985 – 2008).




















Figure 8 Cervical cancer rates in British Columbia, 1970–2008, by 5 year age groups, 20 to 39 years.
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denominator of women with an intact uterus and
masked some of the subsequent effect of cervical screen-
ing. Thirdly, small numbers of cases and deaths in the
youngest age groups make the rates susceptible to spuri-
ous variation related to small changes: including the
effect that we identified of introducing colposcopy in the
1970s, affecting especially women under 30 years. Lastly,
it is desirable to analyze the incidence and mortality
reductions in relation to variations in provincial screen-
ing policies, availability and uptake of screening, and
changes in treatment. Sufficient data is not available to
enable this, and differences between provinces are rela-
tively small in recent years [47].
Conclusions
In Canada, high mortality from cervical cancer in the
1950s has changed to rates that are among the lowest in
the world. The lifetime risk of being diagnosed with cer-
vical cancer has fallen from 1.5% to 0.66% and the risk
of dying has fallen from 0.92% to 0.22%. These effects
are remarkable, given that about 20% of women do not
get smears, or have them infrequently [47]. Many of
the invasive cancers occur among these women, who
ultimately may present with late stage disease. Thus the
protective effect for those who have regular cervical
smears is high. Despite more sporadic screening, most
of the disease reduction has occurred among women
over 40 years. Although initial improvements in mortal-
ity were likely related to improved treatment morerecent improvements are probably largely attributable to
the effect of screening, which likely has also reduced the
need for more aggressive treatment.
Among women below the age of 30 years, cervical
cancer rates have always been low, and have changed
little, so it will be difficult to discern any effect of HPV
immunization until the immunized cohort reaches
beyond the age of 30. The approach to cervical screening
policy may need to change in order to obtain the full
benefit possible. Rather than starting screening at young
ages and frequent re-screening of those who already
participate, further advances are likely to arise from
focusing on the sub-groups of the population that still
have low screening rates.
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